BRAF and melanoma: Indeed, since nearly half of the human melanomas possess a V-RAF murine sarcoma viral oncogene homolog B (BRAF) mutation, BRAF and Mitogen-activated protein kinase kinase (MEK) inhibitors are used for targeted therapies, but with the relevant limitation of chemo-resistance.